Prolactin antagonists and uses thereof

Details Prolactin antagonists and uses thereof Prolactin antagonists and uses thereof

2005-05-10

2005-05-10

Saoud, Christine J. (Department: 1647)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S320100, C536S023510, C514S002600, C514S008100, C514S012200

Reexamination Certificate

active

06890738

ABSTRACT:
Recombinant nucleotide sequences encoding mutated prolactin are described. Expression of the sequences result in mimics of a phosphorylated prolactin corresponding to a selected species. A particularly preferred mimic is mutated at serine 179 (corresponding to human PRL) where serine is substituted by an aspartate residue. This aspartate mutant is a very effective antagonist and shows no ability to stimulate Nb2 to cell proliferation.

REFERENCES:
patent: 4725540 (1988-02-01), Underberg et al.
patent: 4725549 (1988-02-01), Cooke et al.
patent: 5075224 (1991-12-01), Seeburg et al.
Arámburo et al., “Phosphorylation of Prolactin and Growth Hormone,”Journal of Molecular Endocrinology, 8,pp. 183-191 (1992).
Brooks et al., “Preparative Purification of Phosphorylated and Nonphosphorylated Bovine Prolactins,”Molecular and Cellular Endocrinology, 99,pp. 301-305 (1994).
Clevenger et al., “Expression of Prolactin and Prolactin Receptor in Human Breast Carcinoma,”American Journal of Pathology, 146(3), pp. 695-705 (1995).
Cunningham et al., “Mediation of the Binding of Human Growth Hormone to Human Prolactin Receptor,”Science, 250,pp. 1709-1712 (1990).
Fuh et al., “Mechanism-based Design of Prolactin Receptor Antagonists,”The Journal of Biological Chemistry, 268,pp. 5376-5381 (1993).
Goffin et al., “Alanine-Scanning Mutagenesis of Human Prolactin: Importance of the 58-74 Region for Bioactivity,”Molecular Endocrinology, 6(9), pp. 1381-1392 (1992).
Ho et al., “Secretion of Phosphorylated and Non-Phosphorylated Monomer Prolactin Isoforms During Rat Pregnancy and Pseudopregnancy,”Endocrine Journal, 1,pp. 435-439 (1993).
Kim and Brooks, “Isolation and Characterization of Phosphorylated Bovine Prolactin,”Biochem J., 295,pp. 41-47 (1993).
Luck et al., “Analysis of Disulphide Bridge Function in Recombinant Bovine Prolactin Using Site-Specific Mutagenesis and Renaturation Under Mild Alkaline Conditions: A Crucial Role for the Central Disulphide Bride in the Mitogenic Activity of the Hormone,”Protein Engineering, 5(6), pp. 559-567 (1992).
Luck et al., “Bioactive Recombinant Methionyl Bovine Prolactin: Structure-Function Studies Using Site-Specific Mutagenesis,”Molecular Endocrinology, 3(5), pp. 822-831 (1989).
Luck et al., “Single Amino Acid Substitutions in Recombinant Bocvine Prolactin that Markedly Reduce its Mitogenic Activity in Nb2 Cell Cultures, ”Molecular Endocrinology, 5(12), pp. 1880-1886 (1991).
Paris et al., “Bacterial Production and Purification of Recombinant Human Prolactin,”Biotechnology and Applied Biochemistry, 12,pp. 436-449 (1990).
Rhee et al., “Biological Activity and Immunological Reactivity of Human Prolactin Mutants,”Endocrinology, 136(11), pp. 4990-4995 (1995).
Walker, Ameae M., “Phosphorylated and Nonphosphorylated Prolactin Isoforms,”Trends Endocrinol. Metab., 5,pp. 195-200 (1994).
Chen et al., “Development of a Recombinant Prolactin (PRL) Receptor Antagonist, ”Abstract presented at the International Pituitary Congress 4th Satellite Meeting of the International Congress of Endocrinology, San Diego, California, Jun. 16-18, 1996.
Wang and Walker, “Dephosphorylation of Standard Prolactin Produces a More Biologically Active Molecule: Evidence for Antagonism between Nonphosphorylated and Phosphorylated Prolactin in the Stimulation of Nb2Cell Proliferation,”Endocrinology, 133(5), pp. 2156-2160 (1993).
Dialog Serach to Prolactin-, Antagonist- and Hyperprolactinemia, Jan. 1996.
Maciejewski et al., “Mutation of Serine 90 to Glutamic Acid Mimics Phosphorylation of Bovine Prolactin,”The Journal of Biological Chemistry, 270(46), pp. 27661-37665 (1995).
Goffin et al., “Evidence for a Second Receptor Beinding Site on Human Prolactin,”The Journal of Biological Chemistry, 269(51), pp. 32598-32606 (1994).
Chen et al., “Development of a Recombinant Human Prolactin Receptor Antagonists by molecular Mimicry of the Phosphorylated Hormone,”Endocrinology, 139(2), pp. 609-616 (1998).
Wang et al., “Identification of the Major Site of a Rat Prolactin Phosphorylation as Serin 177,”The Journal of Biological Chemistry, 271(5), pp. 2462-2469 (1996).
Oetting et al., “Phosphorylation of Prolactin,”The Journal of Biological Chemistry, 261,v. 4, pp. 1649-1652 (1986).
Greenan et al., “Biosynthesis of the Secreted 24K Isoforms of Prolactin,”Endocrinology, 125,v. 4, pp. 2041-2048 (1989).
Krown et al., “Prolactin Isoform 2 is an Autocrine Growth Factor for GH3Cells,”Endocrinology, 131,v. 2, pp. 595-602 (1992).
Ho et al, Secretion of Specific Nonphosphorylated and Phosphorylated Rat Prolactin Isoforms at Different Stages of the Estorous Cycle,Neuroendocrinology, 58,pp. 160-165 (1993).
Lorenson et al., “Intragranular Prolactin Phosphorylation and Kallikrein Cleavage are Regulated by Zinc and Other Divalent Cations,”Endocrine, 4,v. 3, pp. 249-257 (1996).

Affiliated with

Also associated with

Rating

Prolactin antagonists and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prolactin antagonists and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prolactin antagonists and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3387986